MA45153A - Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux - Google Patents

Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux

Info

Publication number
MA45153A
MA45153A MA045153A MA45153A MA45153A MA 45153 A MA45153 A MA 45153A MA 045153 A MA045153 A MA 045153A MA 45153 A MA45153 A MA 45153A MA 45153 A MA45153 A MA 45153A
Authority
MA
Morocco
Prior art keywords
cancer agents
useful substitute
carbonucleoside
derivatives
carbonucleoside derivatives
Prior art date
Application number
MA045153A
Other languages
English (en)
Other versions
MA45153B1 (fr
Inventor
Robert Arnold Kumpf
Indrawan James Mcalpine
Michele Ann Mctigue
Ryan Patman
Eugene Yuanjin Rui
John Howard Tatlock
Michelle Bich Tran-Dube
Martin James Wythes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA45153A publication Critical patent/MA45153A/fr
Publication of MA45153B1 publication Critical patent/MA45153B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Silicon Polymers (AREA)
MA45153A 2016-06-06 2017-06-03 Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux MA45153B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346226P 2016-06-06 2016-06-06
US201662376856P 2016-08-18 2016-08-18
US201662431714P 2016-12-08 2016-12-08
US201762506076P 2017-05-15 2017-05-15
PCT/IB2017/053295 WO2017212385A1 (fr) 2016-06-06 2017-06-03 Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux

Publications (2)

Publication Number Publication Date
MA45153A true MA45153A (fr) 2021-04-07
MA45153B1 MA45153B1 (fr) 2021-10-29

Family

ID=59071035

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45153A MA45153B1 (fr) 2016-06-06 2017-06-03 Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux

Country Status (42)

Country Link
US (2) US10220037B2 (fr)
EP (1) EP3464249B1 (fr)
JP (2) JP6553825B2 (fr)
KR (2) KR20210018529A (fr)
CN (1) CN109890797B (fr)
AU (2) AU2017279014B2 (fr)
BR (1) BR112018075166A2 (fr)
CA (1) CA2969295A1 (fr)
CL (1) CL2018003504A1 (fr)
CO (1) CO2018013105A2 (fr)
CR (1) CR20180578A (fr)
CU (1) CU24517B1 (fr)
CY (1) CY1124798T1 (fr)
DK (1) DK3464249T3 (fr)
DO (1) DOP2018000268A (fr)
EC (1) ECSP18090743A (fr)
ES (1) ES2890435T3 (fr)
GE (1) GEP20217211B (fr)
HR (1) HRP20211449T1 (fr)
HU (1) HUE056634T2 (fr)
IL (2) IL263505B (fr)
LT (1) LT3464249T (fr)
MA (1) MA45153B1 (fr)
MD (1) MD3464249T2 (fr)
MX (1) MX384948B (fr)
MY (1) MY196413A (fr)
NI (1) NI201800128A (fr)
PE (1) PE20190439A1 (fr)
PH (1) PH12018502535B1 (fr)
PL (1) PL3464249T3 (fr)
PT (1) PT3464249T (fr)
RS (1) RS62351B1 (fr)
RU (1) RU2712944C1 (fr)
SG (2) SG10202100861TA (fr)
SI (1) SI3464249T1 (fr)
SV (1) SV2018005794A (fr)
TN (1) TN2018000424A1 (fr)
TW (2) TWI667240B (fr)
UA (1) UA124386C2 (fr)
UY (1) UY37274A (fr)
WO (1) WO2017212385A1 (fr)
ZA (1) ZA201807723B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
KR20200096265A (ko) * 2017-12-05 2020-08-11 앤젝스 파마수티컬, 인크. Prmt5 억제제로서의 헤테로시클릭 화합물
CN108997309A (zh) * 2018-07-17 2018-12-14 中国科学技术大学苏州研究院 一种吡唑-4-芳基衍生物的制备方法
WO2020033285A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
TWI732431B (zh) * 2019-01-23 2021-07-01 美商輝瑞股份有限公司 多形體
CN114072407A (zh) 2019-04-02 2022-02-18 阿里戈斯治疗公司 靶向prmt5的化合物
JP2022534998A (ja) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｒｍｔ５阻害剤としての複素環式化合物
PT3980417T (pt) 2019-06-10 2023-12-28 Lupin Ltd Inibidores de prmt5
US20220411367A1 (en) * 2019-10-07 2022-12-29 D. E. Shaw Research, Llc Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
CN115135651A (zh) * 2019-12-03 2022-09-30 鲁皮恩有限公司 作为prmt5抑制剂的被取代的核苷类似物
US20230043985A1 (en) 2019-12-18 2023-02-09 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
BR112022010495A2 (pt) * 2020-01-07 2022-09-06 Pfizer Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5
CN111138355A (zh) * 2020-01-17 2020-05-12 成都睿智化学研究有限公司 一种甲醛取代的氮杂稠环类化合物的制备方法
CN115038690A (zh) 2020-01-31 2022-09-09 索尔维公司 用于制造卤代烷基取代的吡啶化合物的方法
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
US20230242539A1 (en) * 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022153161A1 (fr) 2021-01-14 2022-07-21 Pfizer Inc. Traitement du cancer à l'aide d'un inhibiteur de prmt5
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
WO2024118943A2 (fr) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Polythérapie comprenant un inhibiteur de mat2a et un inhibiteur de prmt5
WO2024170488A1 (fr) 2023-02-13 2024-08-22 Astrazeneca Ab Inhibiteur de prmt5 destiné à être utilisé en thérapie anticancéreuse
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026008533A1 (fr) 2024-07-01 2026-01-08 Janssen Pharmaceutica Nv Inhibiteurs de prmt5 pour le traitement d'adénomes
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DK1370531T3 (da) 2001-02-22 2007-06-25 Celltech R&D Ltd Phenylalaninenamidderivater der besidder en cyclobutengruppe, til anvendelse som integrininhibitorer
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP1987717A1 (fr) 2007-04-30 2008-11-05 Bayer CropScience AG Pyridinecarboxamide, agent phytoprotecteur la comportant, son procédé de fabrication et son utilisation
WO2010100475A1 (fr) 2009-03-02 2010-09-10 Astrazeneca Ab Dérivés de l'acide hydroxamique en tant qu'agents contre des bactéries à gram négatif
ES2562010T3 (es) * 2010-12-02 2016-03-02 Medpacto Inc. Derivado de purinilpiridinilamino-2,4-difluorofenilsulfonamida, sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica con actividad inhibidora contra cinasa Raf, que contiene el mismo como ingrediente activo
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
PL2935222T3 (pl) 2012-12-21 2019-02-28 Epizyme Inc Inhibitory PRMT5 i ich zastosowania
WO2015013256A1 (fr) 2013-07-22 2015-01-29 Baylor College Of Medicine Inhibiteurs d'histone méthyltransférase dot1l ne contenant pas de ribose destinés au traitement du cancer
EP3160477A4 (fr) 2014-06-25 2018-07-04 Epizyme, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2016135735A1 (fr) * 2015-02-25 2016-09-01 Outsense Diagnostics Ltd. Analyse de substance corporelle
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物

Also Published As

Publication number Publication date
PE20190439A1 (es) 2019-03-27
AU2017279014A1 (en) 2018-12-13
JP2019521100A (ja) 2019-07-25
EP3464249A1 (fr) 2019-04-10
CR20180578A (es) 2019-03-05
SG10202100861TA (en) 2021-03-30
UA124386C2 (uk) 2021-09-08
CA2969295A1 (fr) 2017-12-06
US20190111060A1 (en) 2019-04-18
PT3464249T (pt) 2021-09-22
MX2018015094A (es) 2019-08-16
MY196413A (en) 2023-03-29
RS62351B1 (sr) 2021-10-29
SG11201810485SA (en) 2018-12-28
CL2018003504A1 (es) 2019-02-01
BR112018075166A2 (pt) 2019-03-26
CN109890797A (zh) 2019-06-14
MA45153B1 (fr) 2021-10-29
MD3464249T2 (ro) 2021-12-31
ECSP18090743A (es) 2019-01-31
CO2018013105A2 (es) 2018-12-28
MX384948B (es) 2025-03-11
AU2019264640A1 (en) 2019-12-05
US10220037B2 (en) 2019-03-05
KR20190015745A (ko) 2019-02-14
KR20210018529A (ko) 2021-02-17
PH12018502535B1 (en) 2022-08-19
IL263505A (en) 2019-01-31
WO2017212385A1 (fr) 2017-12-14
IL282167A (en) 2021-05-31
JP2019194231A (ja) 2019-11-07
LT3464249T (lt) 2021-10-11
TWI637945B (zh) 2018-10-11
ES2890435T3 (es) 2022-01-19
UY37274A (es) 2018-01-31
HRP20211449T1 (hr) 2021-12-24
AU2017279014B2 (en) 2019-08-15
TWI667240B (zh) 2019-08-01
NZ748652A (en) 2021-06-25
PL3464249T3 (pl) 2021-12-20
IL263505B (en) 2021-04-29
TN2018000424A1 (en) 2020-06-15
TW201802074A (zh) 2018-01-16
CU24517B1 (es) 2021-06-08
DOP2018000268A (es) 2019-01-31
US10709709B2 (en) 2020-07-14
EP3464249B1 (fr) 2021-08-11
PH12018502535A1 (en) 2019-10-21
CN109890797B (zh) 2023-02-28
US20170348313A1 (en) 2017-12-07
CU20180144A7 (es) 2019-07-04
CY1124798T1 (el) 2022-11-25
ZA201807723B (en) 2020-01-29
DK3464249T3 (da) 2021-09-06
KR102215313B1 (ko) 2021-02-17
SI3464249T1 (sl) 2021-11-30
HUE056634T2 (hu) 2022-02-28
JP6553825B2 (ja) 2019-07-31
NI201800128A (es) 2019-04-08
TW201840570A (zh) 2018-11-16
GEP20217211B (en) 2021-01-25
RU2712944C1 (ru) 2020-02-03
SV2018005794A (es) 2019-03-19

Similar Documents

Publication Publication Date Title
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA51429A (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
EP3402793A4 (fr) Dérivés de pyridazine en tant qu'activateurs d'eaat2
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase